Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1Phase 1 1

Status

Completed 1

Sponsor Class

NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Uterine Cervical Neoplasms 1Recurrence 1Ovarian Neoplasms 1Limited Stage Small Cell Lung Cancer 1Head and Neck Neoplasms 1Carcinoma, Ovarian Epithelial 1Carcinoma, Hepatocellular 1Alveolar Childhood Rhabdomyosarcoma 1

Interventions

Cisplatin 68Paclitaxel 32Radiotherapy 31Carboplatin 23Bevacizumab 21pembrolizumab 20Brachytherapy 18atezolizumab 11camrelizumab 10Nivolumab 10Gemcitabine 10Drug Therapy 9tislelizumab 8Topotecan 8Taxes 8Chemoradiotherapy 8Radiation 7Docetaxel 7Albumin-Bound Paclitaxel 7zimberelimab 6toripalimab 6nimotuzumab 6Magnetic Resonance Spectroscopy 6Cetuximab 6lenvatinib 5durvalumab 5dostarlimab 5Platinum 5Papillomavirus Vaccines 5Injections 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Uterine Cervical Neoplasms × Tirapazamine × Clear all
NCT00003369 2012-06-14

S9717 Tirapazamine Plus Cisplatin in Treating Patients With Metastatic, Recurrent, or Refractory Cervical Cancer

SWOG Cancer Research Network

Phase 2 Completed
56 enrolled
Gynecologic

Uterine Cervical Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡